You start at a low dose and escalate gradually to minimize side effects, and you stay at your peak dose until you reach your target weight or plateau
[1] [3] Crucially for weight management, these medications act on receptors in the hypothalamus and brainstem areas that regulate appetite and satiety, leading to reduced hunger, increased feelings of fullness, and decreased food intake
Millions of people on Medicare could qualify for obesity treatment, but at todays prices, only a small proportion of them could get the drugs without raising total costs
It has the most published data on CRP reduction and inflammatory marker improvement
However, the relevance of GLP-1 signaling in genetic obesity may extend beyond this bypass mechanism
Ozempic is FDA-approved to help with blood sugar management in people with diabetes, while Wegovy is approved for weight loss in people who are overweight or struggle with obesity